Skip to main content

Table 2 Comparison of KRAS status in tumor tissue and pre-surgery plasma in 242 patients with available paired samples*

From: KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer

  Tumor tissue
Plasma Direct sequencing
  Wild type Mutated Total Kappa p value
Direct sequencing      
Wild-type (%) 138 (57) 63 (26) 201 ·278 <0 · 001
Mutated (%) 11 (5) 30 (12) 41   
Total 149 93 242   
PNA-PCR PNA-PCR
Wild-Type (%) 113 (47) 53 (22) 166 ·456 <0 · 001
Mutated (%) 12 (5) 64 (26) 76   
Total 125 117 242   
  1. *Kappa test was used to estimate the concordance of KRAS status between tumor tissue and plasma samples.
  2. All Wald statistical tests were two-sided.
  3. PNA-PCR, peptide-nucleic-acid-mediated polymerase chain reaction clamping.